QNZ46
Based on 1 publication(s) in Google Scholar
QNZ46 is a highly selective noncompetitive NMDA receptor antagonist targeting GluN2C/D (IC50=3.9 μM), GluN1/GluN2C (IC50=7.1 μM), and GluN1/GluN2D (IC50=182 μM) subunits. QNZ46 inhibits glutamate-mediated calcium influx, thereby blocking excitotoxicity. QNZ46 is membrane permeable and can cross the blood-brain barrier, where it inhibits myelin damage and axonal degeneration.
For research use only. We do not sell to patients.
- Purity: 99.46%
- CAS No.: 1237744-13-6
- Formula: C24H17N3O6
- Molecular Weight:443.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
CNS-Penetrant Compound Library
HY-L028
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Targeted Diversity Library
HY-L099
-
Antidepressant Compound Library
HY-L108
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Ion Channel Compound Library
HY-L166
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) QNZ46
MoreAll iGluR Isoforms
More
Biological Activity
|
NMDA Receptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Oocyte | IC50 |
>300 μM
Compound: 46
|
Antagonist activity at rat recombinant GLuR1 expressed in Xenopus oocytes assessed as inhibition of glutamate-induced current by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant GLuR1 expressed in Xenopus oocytes assessed as inhibition of glutamate-induced current by two-electrode voltage-clamp electrophysiology
|
[PMID: 20684595] |
| Oocyte | IC50 |
>300 μM
Compound: 46
|
Antagonist activity at rat recombinant NR1-NR2B receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant NR1-NR2B receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
|
[PMID: 20684595] |
| Oocyte | IC50 |
229 μM
Compound: 46
|
Antagonist activity at rat recombinant NR1-NR2A receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant NR1-NR2A receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
|
[PMID: 20684595] |
| Oocyte | IC50 |
3 μM
Compound: 46
|
Antagonist activity at rat recombinant NR1-NR2D receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant NR1-NR2D receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
|
[PMID: 20684595] |
| Oocyte | IC50 |
6 μM
Compound: 46
|
Antagonist activity at rat recombinant NR1-NR2C receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant NR1-NR2C receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
|
[PMID: 20684595] |
Cell viability assay: QNZ46 (1-20 μM; 48 h) significantly reduces neuronal cell viability, and the inhibition rate was positively correlated with the concentration[2].
Immunofluorescence assay: QNZ46 (50 μM; 2 h) reduces myelin swelling in the myelin injury model and protected structural integrity[2].
WB assay: QNZ46 (10 μM; 24 h) decreases MLKL phosphorylation and RIP1 expression, may cause suppression of necroptosis pathways[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293 cells expressing GluN1/GluN2D receptors
-
Concentration:1-20 μM
-
Incubation Time:48 h
-
Result:Reduced cell viability by 23-88% (IC50=3.9 μM), consistent with noncompetitive NMDA receptor inhibition.
-
Cell Line:Primary oligodendrocytes
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Reduced ischemic injury-induced myelin decompaction (G-ratio increase from 0.67 to 0.90 μm) and preserved FluoroMyelin Red staining intensity.
-
Cell Line:Rat optic nerve (RON)
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Decreased phosphorylated MLKL (30% reduction) and RIP1 expression (40% reduction), indicating suppression of necroptosis pathways[2].
EAE model: QNZ46 (2 mg/kg+1 mg/kg CP465022; i.p.; once a day for 28 days) significantly reduces clinical scores in experimental autoimmune encephalomyelitis (EAE) mice and protected small-diameter myelinated axons in the spinal cord[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (male, 25-30 g, 8-12 weeks) + transient middle cerebral artery occlusion (tMCAO)[2]
-
Dosage:20 mg/kg (50% DMSO/β-cyclodextrin)
-
Administration:Single i.p. injection 120 min prior to ischemia
-
Result:Reduced infarct volume by 68%, preserved myelinated axons in the external capsule, and improved neurological performance.
-
Animal Model:Animal Model: . C57BL/6 mice (female, 20-22 g, 8-12 weeks) + experimental autoimmune encephalomyelitis (EAE)[3]
-
Dosage:2 mg/kg QNZ46 + 1 mg/kg CP465022 (0.5% methyl cellulose)
-
Administration:Daily i.p. injections from day 0 to day 28 post-immunization
-
Result:Combined QNZ46/CP465022 treatment reduced clinical severity and preserved small-diameter myelinated axons in spinal cord.
Chemical Information
-
CAS No. 1237744-13-6
-
Appearance Solid
-
Molecular Weight 443.41
-
Formula C24H17N3O6
-
Color White to off-white
-
SMILES
O=C(O)C1=CC=C(N2C(/C=C/C3=CC=CC([N+]([O-])=O)=C3)=NC4=C(C=C(OC)C=C4)C2=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Neuropharmacology
Ketamine activated glutamatergic neurotransmission by GABAergic disinhibition in the medial prefrontal cortex. [Abstract]2021 Aug 15:194:108382. PMID: 33144117
Solvent & Solubility
DMSO : 4 mg/mL (9.02 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hansen KB, et al. Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J Neurosci. 2011 Mar 9;31(10):3650-3661. [Content Brief]
[2]. Doyle S, et al. Vesicular glutamate release from central axons contributes to myelin damage. Nat Commun. 2018 Mar 12;9(1):1032. [Content Brief]
[3]. Guo F, et al. Sevoflurane acts as an antidepressant by suppression of GluN2D-containing NMDA receptors on interneurons. Br J Pharmacol. 2024 Sep;181(18):3483-3502. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2552 mL | 11.2762 mL | 22.5525 mL | 56.3812 mL |
| 5 mM | 0.4510 mL | 2.2552 mL | 4.5105 mL | 11.2762 mL |
QNZ46 Related Classifications
HY-15703 Related Classifications
Powered by Bioz